Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 4 of 4 entries
View as:
Phase: N/A
Priority: Normal
Start: 02/29/16
End: 01/10/18
Due: 01/10/19
Phase: N/A
Priority: Normal
Start: 03/07/18
End: 12/03/21
Due: 12/03/22
Phase: N/A
Priority: Normal
Start: 02/26/18
End: 03/20/20
Due: 03/20/21
Phase: N/A
Priority: Normal
Start: 11/13/19
End: 09/22/20
Due: 09/22/21
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| A Study to Investigate the Safety, Tolerability and Pharmacokinetics of ABY-035 | NCT02690142 | Affibody | user2@example.com | None | 2016-02-29 | 2018-01-10 | 2019-01-10 | - | - | 2025-07-14 |
| A Study to Evaluate ABY-035 in Subjects With Moderate-to-severe Plaque Psoriasis | NCT03591887 | Affibody | user2@example.com | None | 2018-03-07 | 2021-12-03 | 2022-12-03 | - | - | 2025-07-14 |
| A Study to Investigate the Safety, Tolerability and Pharmacokinetics of ABY-039 | NCT03502954 | Affibody | user2@example.com | None | 2018-02-26 | 2020-03-20 | 2021-03-20 | - | - | 2025-07-14 |
| A Study to Investigate the Safety, Tolerability, Pharmacokinetic, and Efficacy of ABY-035/AFO2 | NCT03580278 | Affibody | user2@example.com | None | 2019-11-13 | 2020-09-22 | 2021-09-22 | - | - | 2025-07-14 |